Company News »

Jacobs Receives Pharmaceuticals Pilot Plant Contract from Novo Nordisk

Business Wire
Share on StockTwits
Published on

Jacobs Engineering Group Inc. (NYSE:JEC) announced today that it has been awarded a contract from Novo Nordisk for a research and development facility in Bagsvaerd, Denmark.

Officials did not disclose the contract value.

Under the terms of the contract, Jacobs is providing engineering, procurement and construction management services for a new purification pilot plant project, which initially involves one purification line.

The project is expected to expand Novo Nordisks capacity to produce active pharmaceutical ingredients for a growing number of diabetes drugs in development. The pilot plant is expected to be fully operational by late 2016. The facility has the potential to be expanded twofold in the future to provide further production capacity.

In making the announcement, Jacobs Group Vice President Conor Doyle stated, As the largest provider of professional technical services to the biopharmaceutical industry, we look forward to contributing our wide industry knowledge and global perspective on the design of Good Manufacturing Practices facilities to help Novo Nordisk meet their project goals.

We expect the new purification pilot plant to significantly increase our capacity for early-phase diabetes projects, said Jesper Bving, Senior Vice President, CMC Supply, part of Novo Nordisk R&D.

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in areas such as diabetes care. Novo Nordisk employs approximately 40,000 employees in 75 countries and markets its products in more than 180 countries.

Jacobs is one of the world’s largest and most diverse providers of technical professional and construction services.

Statements made in this release that are not based on historical fact are forward-looking statements. We base these forward-looking statements on managements current estimates and expectations as well as currently available competitive, financial and economic data. Forward-looking statements, however, are inherently uncertain. There are a variety of factors that could cause business results to differ materially from our forward-looking statements. For a description of some of the factors which may occur that could cause actual results to differ from our forward-looking statements please refer to our 2013 Form 10-K, and in particular the discussions contained under Items 1 – Business, 1A – Risk Factors, 3 – Legal Proceedings, and 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations. We do not undertake to update any forward-looking statements made herein.

Share on StockTwits